Clinical Benefits and Safety of Gemtuzumab Ozogamicin in Treating Acute Myeloid Leukemia in Various Subgroups: An Updated Systematic Review, Meta-Analysis, and Network Meta-Analysis

Clinical Benefits and Safety of Gemtuzumab Ozogamicin in Treating Acute Myeloid Leukemia in Various Subgroups: An Updated Systematic Review, Meta-Analysis, and Network Meta-Analysis

BackgroundPrevious trials demonstrated evidence involving the total effects of gemtuzumab ozogamicin (GO), an anti-CD33 humanized antibody, on treating acute myeloid leukemia (AML). In this updated systematic review, meta-analysis, and network meta-analysis (NMA), we aimed to comprehensively explore...

Full description

Bibliographic Details
Main Authors: Qingyu Xu, Shujiao He, Li Yu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Immunology
Subjects:
acute myeloid leukemia
gemtuzumab ozogamicin
response
survival
toxicity
meta-analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.683595/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.683595/full

Similar Items